Pemphigus – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:41 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pemphigus – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Personalized Maintenance Therapy with Rituximab and Corticosteroids for Patients with Pemphigus https://clinicaltrials.eu/trial/study-on-personalized-maintenance-therapy-with-rituximab-and-corticosteroids-for-patients-with-pemphigus/ Wed, 29 Apr 2026 15:00:20 +0000 https://clinicaltrials.eu/trial/study-on-personalized-maintenance-therapy-with-rituximab-and-corticosteroids-for-patients-with-pemphigus/ This clinical trial is focused on studying pemphigus, a group of rare skin diseases that cause blisters and sores on the skin and mucous membranes. The study will explore a new approach to maintaining treatment for pemphigus by comparing it with the standard treatment. The standard treatment involves the use of rituximab, a medication given through an infusion into the vein, along with corticosteroids, which are drugs that help reduce inflammation.

The purpose of the study is to see if a personalized treatment plan can better prevent the return of pemphigus symptoms over four years compared to the current standard treatment. This personalized approach will use specific markers in the blood, known as anti-desmoglein antibodies, to identify patients who are at a higher risk of their disease returning. These patients will receive maintenance infusions of rituximab based on their risk level.

Participants in the study will receive either the personalized treatment or the standard treatment. The study will monitor the participants over a period to observe the effectiveness of the treatments in reducing the relapse rate of pemphigus. The study aims to provide insights into whether tailoring treatment based on individual risk factors can offer better outcomes for patients with pemphigus.

]]> Study on Low-Dose Aldesleukin for Patients with Pemphigus, Mucous Membrane Pemphigoid, Polymyositis, Dermatomyositis, and Primary Sclerosing Cholangitis https://clinicaltrials.eu/trial/study-on-low-dose-aldesleukin-for-patients-with-pemphigus-mucous-membrane-pemphigoid-polymyositis-dermatomyositis-and-primary-sclerosing-cholangitis/ Wed, 29 Apr 2026 14:30:30 +0000 https://clinicaltrials.eu/trial/study-on-low-dose-aldesleukin-for-patients-with-pemphigus-mucous-membrane-pemphigoid-polymyositis-dermatomyositis-and-primary-sclerosing-cholangitis/ This clinical trial is focused on studying the safety and effectiveness of a treatment for several chronic inflammatory diseases. The diseases being studied include Mucous Membrane Pemphigoid, Primary Sclerosing Cholangitis, Pemphigus Vulgaris, and Polymyositis/Dermatomyositis. The treatment being tested is a low-dose form of Interleukin-2, also known by its code name IL-2. This medication is administered as a solution for injection or infusion. The study will also use Glucose as part of the trial.

The purpose of this study is to evaluate the safety and the relationship between the body’s immune response and the clinical outcomes when using low-dose IL-2 therapy in patients with these diseases. Participants will receive the treatment over a period of eight weeks. The study is designed to be randomized, meaning participants will be randomly assigned to different groups, and double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or a placebo. This helps ensure the results are unbiased.

Throughout the study, researchers will monitor the participants’ immune responses and any changes in their disease symptoms. The goal is to understand how the treatment affects the immune system and whether it leads to improvements in the conditions being studied. The trial will help determine if low-dose IL-2 therapy is a safe and effective option for managing these chronic inflammatory diseases.

]]>